Provided by Tiger Fintech (Singapore) Pte. Ltd.

MoonLake Immunotherapeutics

51.89
-0.8700-1.65%
Post-market: 51.890.00000.00%17:57 EDT
Volume:303.02K
Turnover:15.68M
Market Cap:3.30B
PE:-18.59
High:52.92
Open:52.92
Low:51.08
Close:52.76
Loading ...

MoonLake Immunotherapeutics Up Nearly 17%, on Pace for Largest Percent Increase Since June 2023 -- Data Talk

Dow Jones
·
03 Jun

RBC Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
03 Jun

MoonLake Immunotherapeutics: Strong Acquisition Interest and Promising Product Pipeline Drive Buy Rating

TIPRANKS
·
03 Jun

Deals of the day-Mergers and acquisitions

Reuters
·
03 Jun

MoonLake Soars 23.5% as Merck Holds Talks to Buy the Biotech Company for over $3 Billion

Reuters
·
03 Jun

PRESS DIGEST- Financial Times - June 3

Reuters
·
03 Jun

24H|MoonLake Surges 17%; Credo Jumps 13%; Applied Digital Gains Another 4% After Soaring 48%

Tiger Newspress
·
03 Jun

BRIEF-Merck Held Talks To Buy Swiss Biotech Moonlake For More Than $3 Bln- FT

Reuters
·
03 Jun

Wolfe upgrades MoonLake Immunotherapeutics ahead of sonelokimab data

TIPRANKS
·
19 May

Stock Track | MoonLake Immunotherapeutics Soars 5.58% Following Wolfe Research Upgrade to Outperform

Stock Track
·
19 May

Wolfe Research Upgrades MoonLake Immunotherapeutics to Outperform From Peer Perform

MT Newswires Live
·
19 May

MoonLake Immunotherap Raised to Outperform From Peer Perform by Wolfe Research

Dow Jones
·
19 May

MoonLake upgraded to Outperform from Peer Perform at Wolfe Research

TIPRANKS
·
19 May

Wedbush Adjusts Price Target on MoonLake Immunotherapeutics to $80 From $78, Maintains Outperform Rating

MT Newswires Live
·
13 May

MoonLake Immunotherap Price Target Maintained With a $66.00/Share by Needham

Dow Jones
·
13 May

Swiss stocks - Factors to watch on May 13

Reuters
·
13 May

MoonLake Immunotherapeutics: Promising Clinical Developments and Market Opportunities Justify Buy Rating

TIPRANKS
·
13 May

MoonLake Immunotherapeutics Q1 Loss Widens

MT Newswires Live
·
13 May

MoonLake Q1 EPS $(0.63) Beats $(0.74) Estimate

Benzinga
·
13 May

MoonLake Immunotherapeutics reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May